New Orleans to Host 2026 Pharmaceutical Science Meeting
The 2026 PharmSci 360 conference will gather experts to discuss the future of drug development and new testing methods.
Updated on Oct. 23, 2026 in Nutrition
Live Poll
Should regulatory agencies prioritize AI-based testing methods over traditional animal testing for new drugs?
The American Association of Pharmaceutical Scientists will host its 2026 PharmSci 360 meeting in New Orleans from October 25 to October 28, 2026. The conference gathers over 7,000 members to discuss evolving standards in drug development and testing.
Why it matters
The event highlights a shifting paradigm in pharmaceutical research, focusing on methods to compress development timelines while maintaining quality. These discussions are relevant as the industry adapts to new FDA guidance regarding non-animal testing requirements.
The American Association of Pharmaceutical Scientists represents a professional body of 7,000 members and publishes 4 peer-reviewed journals. It is currently evaluating industry standards for drug development, though specific regulatory outcomes for new testing models remain under investigation.
The players
Dr. Julie Louise Gerberding
The president and CEO of the Foundation for the National Institutes of Health.
Patrick J. Sinko
The chief science officer for the American Association of Pharmaceutical Scientists.
Thomas Hartung
An expert in toxicology and testing methods scheduled to lead a research track.
Brian Nosek
A researcher known for his work on open science and research credibility.
The details
The conference will explore the transition toward new approach methodologies, such as AI-based computational models and organoids, to replace traditional animal testing. This follows the FDA announcement from April 10, 2025, to phase out animal testing requirements for monoclonal antibodies and other drugs. A collaboration between the association and the US Pharmacopeia will also feature a 2.5-day workshop focused on the complex quality standards required for generic medications.
Timeline
April 10, 2025: The FDA announced a plan to phase out animal testing requirements.
October 25, 2026: The PharmSci 360 meeting begins in New Orleans.
October 26, 2026: Brian Nosek will lead a track focused on research credibility.
October 26-28, 2026: A 2.5-day workshop on complex generics will take place.
October 28, 2026: Thomas Hartung will lead a track on new testing approaches.
Health Landscape
This meeting follows the FDA's 2025 plan to phase out animal testing for monoclonal antibodies, signaling a shift toward computational models. The industry is currently moving to integrate these new methodologies into the standard drug development pipeline.
While this meeting focuses on industry-wide development processes, the shift toward organoid and AI testing models may lead to faster, more accurate clinical trial results for future therapies. Patients should note that these changes aim to improve the quality and safety of new medications.
The takeaway
The movement toward non-animal drug testing methodologies is intended to streamline drug development while preserving high safety standards. Residents interested in clinical advancement may watch for updates on how these new testing approaches influence the timelines for future medications.
Further reading
Learn more about the latest innovations in Nutrition research and industry standards.
Source note: This article includes information reported by BioPharm International.
Live Poll
Should regulatory agencies prioritize AI-based testing methods over traditional animal testing for new drugs?
